Market Cap (In EUR)
1.58 Million
Revenue (In EUR)
543 Thousand
Net Income (In EUR)
-28.77 Million
Avg. Volume
8.33 Million
- Currency
- EUR
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0038-0.08
- PE
- -0.07
- EPS
- -0.04
- Beta Value
- -2.739
- ISIN
- BE0974280126
- CUSIP
- -
- CIK
- -
- Shares
- 585197037.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Prof. François Rieger
- Employee Count
- -
- Website
- https://www.biosenic.com
- Ipo Date
- 2015-02-03
- Details
- BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
More Stocks
-
ELDN
-
EASTW-R
-
PKST
-
CXC
-
023000SAMWONSTEEL Co.,Ltd.
023000
-
002382Blue Sail Medical Co.,Ltd.
002382
-
ACUSAcusphere, Inc.
ACUS
-
MDP